Alligator Bioscience AB

Update in progress

ATORX.ST (Stockholm)

Alligator Bioscience AB (publ) is a Lund, Sweden-based cancer biopharma developing antibody therapies. Key assets: Mitazalimab, a CD40-stimulatory antibody in phase 3 for solid metastatic tumors including pancreatic cancer; ATOR-4066, a tumor-directed bispecific in preclinical; ALG.APV-527, a 4-1BB/5-4 bispecific in phase 2; ATOR-1017, a 4-1BB agonist in phase 1; and HLX22 in phase 3 for metastatic gastric and breast cancers. It also has platforms ALLIGATOR-GOLD, ALLIGATOR-FAB, FIND, RUBY, and collaborations with Aptevo, Orion, BioArctic, Henlius, and Abclon. Founded 2000.